During 2016 and 2017, 229 patients with prostate cancer underwent whole-body MRI and 161 patients aged 71 years (IQR 64–76) and with median PSA 13.0 (IQR 8–28) were eligible for analysis (Fig. 1). This evidence concerns the gene KLK3 and Familial prostate cancer.